There Are Better Drug Stocks Than GlaxoSmithKline - Cramer's Lightning Round (12/7/18)

|
Includes: ABT, CWST, GSK, SITE, WM
by: SA Editor Mohit Manghnani
Summary

Abbott Laboratories is a great buy.

Waste Management is the best of breed.

Stay away from housing stocks.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, December 7.

Bullish Call

Abbott Laboratories (NYSE:ABT): CEO Miles White is doing a good job and the medical device business is good. They also have a good balance sheet and Cramer's trust holds the stock too.

Bearish Calls

SiteOne Landscape Supply (NYSE:SITE): It's associated with the housing group and that's not the place to be.

Casella Waste Systems (NASDAQ:CWST): No. Waste Management (NYSE:WM) is the best pick of the group.

GlaxoSmithKline (NYSE:GSK): "I have not seen what I'd like to see from that company. As far as I'm concerned, there are much better drug stocks to own than Glaxo."

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up